Results 101 to 110 of about 26,895 (263)

Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI

iNew Medicine, EarlyView.
Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang, Yinbo Xu, Yiting Zhao, Liuyi Li, Zhengyi Cheng, Zhongqi Zhang, Yuhang Luo, Qiaoling Liu, Chen Gong, Shichun Shen   +9 more
wiley   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ARE Signaling in MI Rodent

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐
Jiunn‐Jye Sheu, Jui‐Ning Yeh, Han‐Tan Chai, John Y. Chiang, Chi‐Ruei Huang, Jun Guo, Hon‐Kan Yip   +6 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Urinary Collagen Peptides Predict Mortality

PROTEOMICS, EarlyView.
ABSTRACT Organ fibrosis caused by the presence of excessive extracellular matrix (ECM) is related to mortality. Urinary peptide signatures were reported to be predictive of death in SARS‐CoV‐2 and chronic kidney disease. Such signatures were composed for 68% of collagen fragments.
Maria Frantzi, Felix Keller, Agnieszka Latosinska, Joachim Beige, Alexandre Mebazaa, Anaïs Caillard, Dewei An, Paul Perco, Joost P. Schanstra, Lorenzo Catanese, Ralph Wendt, Harald Rupprecht, Jan A. Staessen, Antonia Vlahou, Harald Mischak, Justyna Siwy   +15 more
wiley   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEARTResearch in context

The Lancet Regional Health. Europe
Summary: Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce rates of heart failure hospitalisations and cardiovascular death in patients with type 2 diabetes and prior cardiovascular disease.
Hans Christian Rosén, Moman A. Mohammad, Tomas Jernberg, Stefan James, Jonas Oldgren, David Erlinge   +5 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients

Virology Journal
Background Long COVID presents significant health challenges, especially for patients with type 2 diabetes. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors may provide protective effects against COVID-19 complications ...
Han-Wei Yeh, Chung-Hsien Chaou, Shun-Fa Yang, Yu-Hsun Wang, Yu-Hsiang Kuan, Chao-Bin Yeh   +5 more
doaj   +1 more source